Bristol-Myers Squibb Company (BMY)vsViking Holdings Ltd (VIK)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
VIK
Viking Holdings Ltd
$82.67
-1.55%
CONSUMER CYCLICAL · Cap: $37.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 646% more annual revenue ($48.48B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 15.0%. BMY trades at a lower P/E of 15.7x. VIK earns a higher WallStSmart Score of 66/100 (B-).
BMY
Buy60
out of 100
Grade: C+
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Intrinsic value data unavailable for VIK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Every $100 of equity generates 255 in profit
Earnings expanding 226.6% YoY
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.7x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : VIK
The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.
Key Dynamics to Monitor
BMY profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK carries more volatility with a beta of 1.57 — expect wider price swings.
VIK is growing revenue faster at 27.8% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Bottom Line
VIK scores higher overall (66/100 vs 60/100), backed by strong 17.6% margins and 27.8% revenue growth. BMY offers better value entry with a 32.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?